MX2020008456A - Uso de tradipitant para tratar la cinetosis. - Google Patents

Uso de tradipitant para tratar la cinetosis.

Info

Publication number
MX2020008456A
MX2020008456A MX2020008456A MX2020008456A MX2020008456A MX 2020008456 A MX2020008456 A MX 2020008456A MX 2020008456 A MX2020008456 A MX 2020008456A MX 2020008456 A MX2020008456 A MX 2020008456A MX 2020008456 A MX2020008456 A MX 2020008456A
Authority
MX
Mexico
Prior art keywords
tradipitant
motion sickness
symptom
treating
treatment
Prior art date
Application number
MX2020008456A
Other languages
English (en)
Spanish (es)
Inventor
Polymeropoulos Mihael H
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2020008456A publication Critical patent/MX2020008456A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
MX2020008456A 2018-09-28 2019-09-26 Uso de tradipitant para tratar la cinetosis. MX2020008456A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737992P 2018-09-28 2018-09-28
US201962874927P 2019-07-16 2019-07-16
PCT/US2019/053107 WO2020069092A1 (en) 2018-09-28 2019-09-26 Use of tradipitant in motion sickness

Publications (1)

Publication Number Publication Date
MX2020008456A true MX2020008456A (es) 2020-09-25

Family

ID=68165866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008456A MX2020008456A (es) 2018-09-28 2019-09-26 Uso de tradipitant para tratar la cinetosis.

Country Status (20)

Country Link
US (2) US20220249444A1 (https=)
EP (2) EP3856338B1 (https=)
JP (1) JP7468964B2 (https=)
KR (2) KR102863233B1 (https=)
CN (1) CN111918701B (https=)
AU (1) AU2019348001B2 (https=)
BR (1) BR112020015484A2 (https=)
CA (1) CA3089238A1 (https=)
CL (1) CL2020002165A1 (https=)
DK (1) DK3856338T3 (https=)
ES (1) ES3010832T3 (https=)
FI (1) FI3856338T3 (https=)
HR (1) HRP20250097T1 (https=)
HU (1) HUE070000T2 (https=)
IL (1) IL281569B2 (https=)
MX (1) MX2020008456A (https=)
PT (1) PT3856338T (https=)
SI (1) SI3856338T1 (https=)
WO (1) WO2020069092A1 (https=)
ZA (1) ZA202004594B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2824552T3 (es) * 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) * 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
AU2003230829B8 (en) * 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
BRPI0415010B8 (pt) * 2003-10-24 2021-05-25 Lilly Co Eli formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida
EP2722045B1 (en) * 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
ES2824552T3 (es) * 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法

Also Published As

Publication number Publication date
JP2022511194A (ja) 2022-01-31
JP7468964B2 (ja) 2024-04-16
EP3856338B1 (en) 2024-11-06
CL2020002165A1 (es) 2021-01-04
HRP20250097T1 (hr) 2025-03-28
CN111918701B (zh) 2024-08-02
BR112020015484A2 (pt) 2021-04-27
EP3856338A1 (en) 2021-08-04
NZ766397A (en) 2023-09-29
KR20250140634A (ko) 2025-09-25
ES3010832T3 (en) 2025-04-04
CA3089238A1 (en) 2020-04-02
EP4450126A3 (en) 2025-02-19
SI3856338T1 (sl) 2025-04-30
US20240285588A1 (en) 2024-08-29
US20220249444A1 (en) 2022-08-11
IL281569A (en) 2021-05-31
HUE070000T2 (hu) 2025-04-28
AU2019348001A1 (en) 2020-08-06
AU2019348001B2 (en) 2023-09-21
EP4450126A2 (en) 2024-10-23
PT3856338T (pt) 2025-01-31
FI3856338T3 (fi) 2025-02-03
IL281569B2 (en) 2025-04-01
IL281569B1 (en) 2024-12-01
ZA202004594B (en) 2024-12-18
WO2020069092A1 (en) 2020-04-02
DK3856338T3 (da) 2025-02-10
CN111918701A (zh) 2020-11-10
KR20210067980A (ko) 2021-06-08
KR102863233B1 (ko) 2025-09-22

Similar Documents

Publication Publication Date Title
MX2020008456A (es) Uso de tradipitant para tratar la cinetosis.
CL2020000272A1 (es) Compuesto heterocíclico y su uso.
MX2021008191A (es) Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña.
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
CL2020001290A1 (es) Método para el tratamiento de enfermedades gastrointestinales con tradipitant.
MX389468B (es) Gliceril 3-hidroxibutiratos para el control de los síntomas de la migraña
MX2017011459A (es) Metodos para el tratamiento de trastornos del movimiento involuntario anormal.
PE20180673A1 (es) Tratamiento contra el cancer por manipulacion de la microflora comensal
AR113440A1 (es) Tratamiento de glomeruloesclerosis focal y segmentaria con antagonistas de ccr2
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
NI202100056A (es) Moduladores de la expresión de hsd17b13
MX388834B (es) Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes.
JOP20210050B1 (ar) معدلات تعبير pnpla3
CL2018003451A1 (es) Moduladores del receptor adrenergico beta-3 que sirve para el tratamiento o la prevensión de desordenes relacionados.
MX384989B (es) Uso de un agonista del receptor x retinoide (rxr) en combinación con una hormona tiroidea para el tratamiento de esclerosis múltiple.
AR110404A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
MX2019015150A (es) Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión.
EA202091881A1 (ru) Соединения для лечения боли
AR100231A1 (es) Composiciones para el cuidado de las telas que comprenden polímeros de poliuretano, poliurea y/o poliuretanourea
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX379289B (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
AR106487A1 (es) Antagonistas de receptores de cgrp